[Frontiers in Bioscience 15, 226-236, January 1, 2010]
Role of myoepithelial cells in breast tumor progression
Puspa Raj Pandey1, Jamila Saidou1, Kounosuke Watabe1
1
TABLE OF CONTENTS
1. ABSTRACT
Myoepithelial cells form a semi-continuous protective sheet separating the human breast epithelium and the surrounding stroma. They suppress stromal invasion of tumor cells by the secretion of various anti-angiogenic and anti-invasive factors. The disruption of this cell layer results in the release of the growth factors, angiogenic factors, and reactive oxygen species causing an alteration in the microenvironment. This helps in the proliferation of surrounding cells and increases the invasiveness of tumor cells. Two theories are proposed for the mechanism of tumor epithelial cells progression from in situ to invasive stage. According to the first theory, tumor cell invasion is triggered by the overproduction of proteolytic enzymes by myoepithelial cells and surrounding tumor cells. The second theory states that tumor invasion is a multistep process, the interactions between damaged myoepithelial cells and the immunoreactive cells trigger the release of basement membrane degrading enzymes causing tumor progression. Further studies in understanding of molecular mechanism of myoepithelial cell functions in tumor suppression may lead to the identification of novel therapeutic targets for breast cancer.
2. INTRODUCTION
The mammary glands contain a branching ductal network which is composed of two epithelial cell types present in roughly equal numbers and are embedded in connective tissue. They are an incomplete outer layer of elongated myoepithelial cells and an inner layer of polarized luminal epithelial cells, and both of these cell layers are surrounded by a continuous lining called basement membrane (BM) (Fig 1) (1). Myoepithelial cells contribute to the synthesis of a surrounding BM, and their myogenic differentiation is responsible for the contractile phenotype mediated by oxytocin (2). BM is composed of the collagenous stroma and is rich in laminin, heparan sulfate proteoglycans, glycosaminoglycans and entactin. Myoepithelial cells are attached to luminal cells by desmosomes and to the BM by hemidesmosomes (1). They are contractile cells which contain alpha-smooth muscle actin (alpha-SMA) and adhere to the basement membrane. These cells are elongated in shape and joined to each other by intermediate or gap junctions and a number of intercellular adhesion molecules, forming a semi-continuous sheet or belt that encircles the epithelial cells. Thus, myoepithelial cells form a natural border to separate proliferating epithelial cells from the BM and underlying stroma (3).
Both the myoepithelial cell layer and the BM act as a natural barrier and are selectively permeable to the passage of small molecules. Due to this structural feature, nutrients, growth factors and other chemotropic molecules must first pass through the BM then the myoepithelial cells to reach the inside of the duct, and most tumor epithelial cells have to first pass through the myoepithelial cell layer and then the BM in order to physically contact the stroma (Fig 2) (1,3). In other words, the disruption of both the BM and the myoepithelial cell layer is an absolute prerequisite for breast tumor invasion (4). Human breast myoepithelial cells have the property of self-renewal and they consistently undergo both proliferation and differentiation to replace injured, aged or dead myoepithelial cells. The division of myoepithelial cells in the adult breast in vivo is relatively slow whereas luminal epithelial cells multiply rather quickly with each menstrual cycle and the number is increased greatly during the lactating period. On the contrary, when the myoepithelial cells are cultured in in vitro, they divide more rapidly than the luminal cells which make it problematic to study the luminal cells in in vitro culture as the residual myoepithelial cells in sorted luminal cultures will divide rapidly and outgrow luminal cells (5, 6).
The importance of myoepithelial cells in breast tumor progression has always been under- estimated; however, it is now being recognized that besides milk ejection during lactation they have an important role in the suppression of tumor invasion. On the other hand, degradation of this layer promotes breast tumor progression and metastasis, although the exact mechanisms of this phenomenon are still unclear (7). In this review, we overview recent information about the general characteristics of myoepithelial cells, their roles in tumor suppression, tumor microenvironment alteration and progression in breast cancer. Understanding the underlying molecular mechanisms of the myoepithelial cell functions during tumor progression may lead to the identification of novel therapeutic targets.
3. CHARACTERISTICS OF MYOEPITHELIAL CELLS
3.1. Structural features of myoepithelial cells
Myoepithelial cells contain a large amount of microfilaments and smooth muscle-specific cytoskeletal proteins such as alpha-actin and myosin that are responsible for the contractile phenotype mediated by oxytocin during lactation (2). Myoepithelial cells are slightly spindle or elongated in shape with pale cytoplasm and nuclei and are keratin-positive. They are distinct from myofibroblasts which are mesenchymal cells and positive for vimentin and are also generally positive for alpha-SMA, cytokeratin 5/6 and other high molecular weight cytokeratins, p63 and caldesmon (8). Each myoepithelial cell has long cytoplasmic processes that wrap around a secretory unit and hence, contraction of the myoepithelial processes can eject secretory product from the secretory unit into its duct. The myoepithelial cells play an active role in branching morphogenesis of the mammary gland, and their correct recognition and detection is crucial in the diagnosis of a number of pathological breast lesions (9). Several markers have been reported for the immunohistochemical detection of breast myoepithelial cells such as alpha-SMA, smooth muscle myosin heavy chain, h-caldesmon, S100 protein, p63, maspin and specific cytokeratins like CTK14 and CTK17. Other myoepithelial cell-specific proteins include CD10/CALLA, calponin, and epidermal growth factor receptor (EGFR); however, the specificity and sensitivity of these markers vary widely. Of these, maspin and p63 are generally considered the most promising markers for myoepithelial cells. (10). In addition to these genes, Barsky et al. used microarrays to analyze established myoepithelial cell lines and compared them to normal and cancerous cell lines as well as primary tumors. Using this approach, they identified many genes that encode extracellular matrix proteins (collagens, laminin, fibronectin and osteonectin), proteins involved in angiogenesis (thrombospondin-1 and plasminogen) and protease inhibitors (maspin and PAI-1). The suppression profile of these specific genes in myoepithelial cells strongly suggest that they act as natural tumor suppressors (11).
3.2. Normal functions of myoepithelial cells
Myoepithelial cells normally surround ducts and acini of glandular organs and contribute to the synthesis of a surrounding basement membrane (12). The most obvious and important function of the myoepithelial cell in the breast is contraction of mammary gland duct. Myoepithelial cells are attached to the luminal cells and control many aspects of luminal functions. They regulate the flow of fluid and control the entry and exit of nutrients, electrolytes and other growth factors. Myoepithelial cells also process signals of endocrine or paracrine nature, and perhaps as an intermediary in such signaling processes by passing information both inwards and outwards in a paracrine fashion or via intra-epithelial gap-junctions (1). Another important function of myoepithelial cells is to form a structural barrier between stroma and lumen as they generate a continuous layer like a sheet. Because of this location, the tumor cells can invade the stroma only after the disruption of myoepithelial cells and the basement membrane which is an absolute requirement for tumor invasion. Importantly, myoepithelial cells also modulate the expression of matrix metalloproteinases (MMPs) in the tumor as well as in the surrounding cells and help in the prevention of tumor invasion which may be mediated by these proteolytic enzymes (13). Several angiogenesis-related MMPs such as MMP19 are secreted by the normal myoepithelial cells and this enzyme is also reported to participate in the turnover of extracellular matrix (ECM) (14).
Ductal elongation requires the production and organization of new BM, and myoepithelial cells play a key role in this process. Myoepithelial cells synthesize BM components such as collagen IV, laminin-1, laminin-5 and fibronectin that regulate ductal growth, and facilitate the sculpting of new BM through the production of MMP2 and MMP3 (13, 14). Myoepithelial cells also express morphogens and growth factors that are activated in a coordinated manner during morphogenesis (1). Normal myoepithelial cells are critical for correct polarity of luminal epithelial cells, most likely via production of laminin-1. On the other hand, myoepithelial cells present in invasive breast carcinoma have many traits in common with normal myoepithelial cells but they show either complete absence or reduced expression of laminin-1. Laminin-1 is strongly expressed around normal breast epithelial structures and thus tumor myoepithelial cells are unable to induce the polarization of luminal epithelial cells (15). Interestingly, recent work from the Polyak laboratory has shown that myoepithelial cells isolated from DCIS are drastically altered and secrete many cytokines and other potential tumor promoting molecules (10).
3.3. Myoepithelial cells are natural tumor suppressors
Myoepithelial cells, which surround ducts and acini of glandular organs, form a natural border separating proliferating epithelial cells from basement membrane and underlying stroma, thus physically preventing tumor cell invasion. Several lines of evidence suggest that differentiated myoepithelial cells block proliferation of breast carcinoma cells by inducing growth arrest and apoptosis. In addition, myoepithelial cells also secrete various effector and inhibitor molecules that interfere with the invasive behavior of tumor cells, block angiogenesis and the BM degradation (1, 3). Myoepithelial cells have also been shown to modulate the gene expression of both tumor cell and fibroblast by antagonizing the tumor-stroma interactions that have been demonstrated as a critical factor in tumor progression (13). The modulation of MMP expression is perhaps the most important effect of myoepithelial cells. The MMPs are inhibited by specific endogenous tissue inhibitor of metalloproteinases (TIMPs), which comprise a family of four protease inhibitors: TIMP1, TIMP2, TIMP3 and TIMP4. TIMP-1 is mainly secreted by the myoepithelial cells (11, 21). However, the exact mechanism by which they block MMP expression is not clearly understood. In addition, myoepithelial cells constitutively express high amounts of proteinase inhibitors that include maspin, activin, connexin, thrombospondin, TIMP-1, protease nexin-II, alpha-1 antitrypsin and neogenin (Table 1). These proteinase inhibitors act by blocking the activity of the released enzyme rather than by inhibiting the proteolytic enzyme synthesis (12, 13).
Maspin is one of the most important tumor suppressors that are secreted by myoepithelial cells. It is a member of the serpin family of serine proteases which inhibits tumorigenesis, tumor cell migration and metastasic spread thus it functions as a tumor suppressor. It is also detectable in breast ductal lavage fluid and breast nipple aspirates (15). Maspin is secreted in large quantities by the normal cells whereas tumor cells do not secrete it. This suggests that maspin has tumor suppressor function in normal cells but this function is lost in tumor cells. In addition, maspin acts as an angiogenesis inhibitor and locomotion inhibitor (16, 17). These properties may explain the anti-angiogenic and anti-invasive effects of myoepithelial cells on tumor and precancerous cells. Therefore, myoepithelial cells are considered to be natural suppressors of invasion and metastasis and may specifically inhibit the progression of precancerous disease states to invasive cancer (15-20).
Caveolins are a family of proteins that are involved in receptor independent endocytosis and high expression of caveolins leads to inhibition of growth factor signaling pathways (22). Caveolin-1 was found to be downregulated in breast cancer specimens as well as in human breast cancer cell lines compared with matched normal tissue and normal epithelial cell lines (23-24). It has also been demonstrated that caveolin-1 reduces both primary tumor growth and spontaneous metastasis to lung and bone (25). myoepithelial cells secrete another class of tumor suppressors, cytokeratins (CK) which are intermediate filament keratins found in the intracytoplasmic cytoskeleton of epithelial tissue. Steffansson et al. found that loss of CK5/6 was associated with features of aggressive tumors and lack of CK5/6 was significantly associated with reduced survival in large population-based series of 276 endometrial carcinomas with long and complete follow-up (26). It was reported in another study that there was a highly significant relationship between loss of CK5/6 expression and reduced membranous beta-catenin staining and that the reduction of membranous beta-catenin expression was associated with aggressive tumors and decreased survival in this tumor series (27). Relaxin is a peptide hormone secreted by Myoepithelial cells which is capable of stimulating the production of nitric oxide (NO) in several cell types. NO has been reported to have anti-tumor activity by inhibiting proliferation, promoting differentiation, and reducing the metastatic spread of some tumor cell types such as in MCF-7 cells (30).
Myoepithelial cells express activin, which belongs to the TGF-beta superfamily. Mutations in activin receptors have been indeed associated with pancreatic and pituitary tumors (31-32). Activin has been reported to inhibit growth of breast cancer cells by activating Smad proteins and by blocking the p38 mitogen-activated protein kinase (MAPK) pathway (33). Connexins (Cx), or gap junction proteins, belong to a family of structurally-related transmembrane proteins that assemble to form gap junctions. Connexins are tumor suppressors, and Cx-26 and Cx-43 gap junctions are often down-regulated in breast cancer. The downregulation of connexin expression is often observed in tumors and transformed cell lines and is believed to contribute to the loss of cell growth control (34). Xu et al. reported that Cx-43 may induce E-cadherin expression and inhibit cell proliferation and progression of lung cancer (35). Thrombospondin-1 (TSP-1) is another natural tumor suppressor secreted by myoepithelial cells which is a 430-kd glycoprotein that is an important component of the ECM and is known to be a potent inhibitor of angiogenesis both in vitro and in vivo. TSP-1 possesses tumor suppressor function, possibly through its ability to inhibit tumor neovascularization and this gene appears to be regulated by p53, a gene which is mutated in as high as 50% of advanced breast cancers (36).
A new protein known as myoepithelium-derived serine proteinase inhibitor (MEPI) was recently identified exclusively in the myoepithelial cells on the normal and noninvasive mammary epithelial side of the basement membrane, while MEPI expression was not detected in the malignant breast carcinomas (37). Expression of MEPI in human breast cancer cells, blocks their growth, decreases their invasive potential and prevents tumor dissemination in vivo (37). Thus, the expression of MEPI in myoepithelial cells may prevent breast cancer progression and metastasis. Myoepithelial cells also express neogenin which is a receptor initially identified to act in short and long range neuronal guidance and cap cells in terminal end buds (TEBs), a specialized structure at the end of growing ducts. Neogenin is a member of the N-CAM family of cell adhesion molecules and is closely related to the DCC tumor suppressor gene product (38). In fact, Lee et al. reported that the expression of neogenin was inversely related to the tumorigenicity of human breast cancer (39). They used tissue array and found that all of the normal breast tissues showed a strong neogenin expression, while most cancer tissues showed weaker neogenin expression compared to normal tissues. These results suggest that neogenin expression in myoepithelial cells has an important function in suppression of mammary tumorigenesis. In addition to producing these anti-invasive and anti-angiogenic molecules, myoepithelial cells have been shown to possess CD44 shedding activity by producing soluble CD44, which blocks the adhesion and migration of human carcinoma cells on hyaluronic acid-coated surfaces (40). All these observations strongly support the notion that myoepithelial cells function as tumor suppressors.
4. ROLES OF MYOEPITHELIAL CELLS IN TUMOR PROGRESSION
Tissue microenvironment has profound effects on the progression of cancer cells by its paracrine signaling. Molecular characterization of various cell types from the normal breast tissue, ductal carcinoma in situ (DCIS) and invasive breast tumor revealed significant changes in gene profile in all cell types during breast tumor progression. Microenvironment changes influence tumor progression as well as the efficacy of various cancer therapies. Alteration in tissue organization and homeostasis can precede and increase the chance of tumor initiation as exemplified by the increased cancer risk associated with chronic inflammation and wound healing (41). Paracrine factors such as extracellular proteins, protease inhibitors, various growth factors, angiogenesis regulators and other unidentified factors secreted by myoepithelial cells exert their effects on the tumor epithelial cells. Such regulation may be important in determining tumor cell behavior in vivo and may be mediated by specific ECM molecules, matrix associated growth factors or host cell themselves (42). Myoepithelial cells contribute to the synthesis and remodeling of the basal lamina and the basement membrane. They exert important paracrine effects on normal glandular epithelium, and there are several lines of evidence to indicate that myoepithelial cells regulate the progression of DCIS to invasive breast cancer (1). On the contrary, myoepithelial cells also exhibit a tumor suppressor phenotype and they rarely transform themselves; however, when they transform, they generally give rise to benign neoplasms that grow without degrading ECM (11).
The comparison of myoepithelial cells derived from normal breast tissue with myoepithelial cells that surround spaces involved by DCIS have showed a significant difference in the gene expression profiles in several respects (43). Most of the over-expressed genes in DCIS- associated myoepithelial cells encode secreted cell surface proteins, several of which are chemokines, such as, SDF1/CXCL12 and CXCL14 which bind to receptors on epithelial cells and enhance their proliferation, migration, invasion and stromal angiogenesis whereas a variety of genes are downregulated in the DCIS- associated myoepithelial cells which are involved in normal functions including those for oxytocin receptors, laminin and TSP-1. DCIS- associated myoepithelial cells also upregulate the synthesis of enzymes involved in the degradation of ECM and BM such as MMPs (43). Myoepithelial cell lines such as HMS-16 which are derived from benign myoepithelial tumors, express high levels of active anti-angiogenic factors that include maspin, TIMP-1, TSP-1 and soluble bFGF receptors but very low levels of angiogenic factors thus, secretory factors from myoepithelial cells can change the tumor microenvironment and the signaling molecules such as chemokines may play a role in breast tumorigenesis by acting as paracrine factors (44). These results provide strong evidence that DCIS- associated myoepithelial cells show abnormal behavior and because of this, they lost their normal tumor suppressor functions and lead to the progression of DCIS to invasive breast cancer (10- 11, 43-44).
4.1 Roles of myoepithelial cells in the alteration of microenvironment and breast tumor progression
As already mentioned, myoepithelial cells act as natural tumor suppressors by secreting the various molecules that have inhibitory effects on tumor cell growth, invasion and angiogenesis. They also act as a physical barrier to prevent the invasion of tumor cells from the duct to the stroma. It is generally accepted that primary breast carcinomas show a dramatic increase in the ratio of luminal epithelial cells to myoepithelial cells. In the later stages of breast cancer, the ducts completely lack myoepithelial cells (45). Thus, it is mandatory for this layer to be disrupted in order for the tumor to spread and metastasize. It has been speculated that most of these secretory molecules act in a paracrine manner so that a disruption in the myoepithelial cell layer can result in the release of these factors and possibly alter the tumor microenvironment which ultimately results in metastasis to other organs (3, 7). Numerous studies in cell culture and in xenograft models have demonstrated that paracrine interaction between stromal and tumor epithelial cells promote the proliferation, invasiveness, tumorigenicity and metastatic potential of immortalized epithelial cells or cancer cells (46-48).
It is generally believed that development of breast cancer is a multi-step process which progresses from normal to hyperplastic to in situ and finally to invasive stages (49). One distinct feature of the invasive tumor is disappearance of the myoepithelial cell layer although the exact mechanism for this phenomenon is unknown. It may be possible that the myoepithelial cells are degraded by the overproduction of the degradative enzymes or they are selectively eliminated by apoptotic mechanism (50-51). Alternatively, the stem cells in that area stop differentiating into myoepithelial cells. In any of these cases, once this protective layer is lost, the tumor cells can easily invade the stroma and metastasize to other organs. Tumor progression occurs when there is a change in microenvironment due to the secretions from myoepithelial cells (51).
There are two major hypotheses that explain the mechanism of tumor progression from in situ to stromal tumor invasion. One is proteolytic enzymes theory which is based on the overproduction of MMPs by the myoepithelial cells and surrounding tumor cells and the other theory is known as focal myoepithelial cell layer disruption (FMCLD theory) (4, 7, 50). FMCLD theory states that the breast tumor invasion is a multi-step mechanism which occurs in a series of events when myoepithelial cells, damaged by genetic abnormalities or any physical injuries, secrete various effector molecules which alter the microenvironment. Myoepithelial cells could be the target of external and internal insults and are also affected by a variety of normal and pathologic changes. For instance, exposure of myoepithelial cells to oxytocin results in the enhancement of myoepithelial cell differentiation and proliferation whereas exposure to lambda carrageenans, naturally occurring sulfated polysaccharides which are used in the commercial food preparation, could result in the disassembly of the filaments and loss of myoepithelial cells; however, the exact mechanism by which these chemicals cause the destruction of myoepithelial cells is still unknown (51-52).
4.1.1. Proteolytic enzymes theory
In order to invade the stroma and metastasize, tumor cells have to cross several barriers like BM, myoepithelial cell layer, interstitial tissues and extracellular matrices, which are composed primarily of collagen, proteoglycans, laminin, elastin, and other glycoproteins. Tumor cells over-express and secrete proteases which are capable of degrading the components of these barriers and thus facilitate their migration. According to the proteolytic enzyme theory, the progression from the in situ to invasive stage is believed to be triggered by the overproduction of various proteolytic enzymes by the tumor cells, such as MMPs, serine proteases and cathepsins resulting in the degradation of the BM (53). The most important among these proteolytic enzymes are MMPs, which are able to degrade the BM and make it easier for the tumor cells to cross the previously intact barrier and to invade the stroma. Ultimately, the invaded cells metastasize to other distant organs and colonize there resulting in micro or macrometastases (54-55). It was found that the level of proteolytic enzymes increases linearly with tumor progression and reaches the highest level at the in situ stage in which invasion occurs (54). MMPs are not solely responsible for BM degradation because the inhibitors of these proteolytic enzymes do not inhibit the tumor invasion completely. It is possible that there are some other secretory factors or mechanisms by which the normal microenvironment is changed, which results in degradation of the BM. In the case of DCIS, it may be possible that the tumor cells induce myoepithelial cells and luminal cells to secrete additional factors which can degrade the BM.
4.1.2. Focal myoepithelial cell layer disruption (FMCLD) theory
Recently, a new model of tumor invasion of stroma by the epithelial cells was proposed by Man et al. (Fig 3) (4). According to this model, tumor invasion is triggered by a series of events which begin when the myoepithelial cells are damaged by any genetic abnormalities, inflammation, mutations, localized trauma or other physical/chemical injuries which result in the disruption of the myoepithelial cell layer or impairs the normal replacement process. In fact, it is now known that disruption in the myoepithelial cell layer is the most distinct sign of tumor invasion in breast cancer. The death of myoepithelial cells results in a localized loss of tumor suppressors like maspin, TIMPs and other proteases and paracrine inhibitory factors. The diffusion of these molecules in the microenvironment increases permeability for oxygen, nutrients, and growth factors, and a localized increase in leukocyte infiltration, leading to substantial alterations of the microenvironment that facilitate cell proliferation, locomotion and stromal invasion (4,7). The infiltration of immunoreactive (IRC) cells such as leucocytes and macrophages into the damaged site results in the release of digestive enzymes that destroy the myoepithelial cells. The damaged myoepithelial cells also release MMPs and other proteases which in turn cause the focal disruption in the myoepithelial cell layer and ultimately degrade the BM producing a gap. Once the BM integrity is compromised, tumor cells can cross the damaged BM and come in contact with the stroma and colonize there. This altered microenvironment leads to variable consequences in overlying tumor and adjacent myoepithelial cells, depending on the nature of these cells. Indeed this stromal-epithelial interaction is another important factor in the alteration of microenvironment that plays a significant role in the transition from DCIS to invasive breast cancer. The direct physical contact between the tumor cells and stromal cells stimulates the production of tenascin and other invasion-associated molecules that influence tumor cell proliferation, differentiation, angiogenesis, facilitate tissue remodeling and epithelial-mesenchymal transition by providing a favorable microenvironment in the stromal region (4, 7).
The proteolytic enzyme theory was widely accepted in the past; however, it is becoming clear that some other factors and interactions also take place during BM degradation and stromal invasion. The interactions between the myoepithelial cells in the ducts and the fibroblasts present in the stromal compartment are known to influence tumor progression; tumor-associated fibroblasts (TAFs) have been shown to promote tumor cell invasion by releasing extracellular matrix (ECM) degrading proteases and these enzymes consequently modify the composition of the ECM and facilitate tumor cell motility (56-57). Besides MMPS, some other proteolytic enzymes like serine proteases and cathepsins are also indicated for BM degradation. But the exact mechanism of the interactions between these cell types is not fully understood (53). There were several clinical trials for various MMP inhibitors; however, they failed to block the tumor invasion in patients which suggest that this proteolytic enzyme theory is inadequate to completely reflect the molecular mechanisms of the tumor invasion. Therefore, the FMCLD theory has some advantages over proteolytic theory because it focuses on the interaction of the different types of cells present in the tumor microenvironment. The localized death of myoepithelial cells causes the release of its inner contents like the proteolytic enzymes and growth factors. The resulting immunoreactions that accompany an external environmental insult or internal genetic alterations are triggering factors for further disruptions of the myoepithelial cell layer, BM degradation, and subsequent tumor progression and invasion (4, 7). However, the FMCLD theory failed to determine the significance of acidic microenvironment and how it affects the tumor invasiveness and progression.
4. CLINICAL IMPLICATIONS OF MYOEPITHELIAL CELL STAINING
The presence of myoepithelial cells has long been recognized as a prominent feature of benign breast diseases using different types of staining procedures. Presence or absence of an intact myoepithelial cell layer around the luminal cells is by far the major diagnostic criteria that pathologists use to differentiate in situ from invasive carcinomas (58). Confirmation of the myoepithelial cell layer on routine cytology or histology can be done with the help of alpha-SMA immunostaining; however, these cells can also be identified by S-100 (59), calponin (60), h-caldesmon (60-61), smooth muscle heavy chain (SMMHC) antibodies (60-61) and CD10 (62). Foschini et al. (60) showed that SMMHC is more specific for myoepithelial cells in the breast, while Masood et al. demonstrated significant difference in the number of myoepithelial cells in benign versus malignant tumors (63). Bofin et al. also noted that myoepithelial cells are virtually absent or markedly reduced in invasive carcinoma compared to DCIS lesions, therefore, the myoepithelial cell is an important marker to distinguish benign, proliferative breast diseases (PBD) and frank malignant breast lesions (64). Furthermore, Yu et al. quantified the number of myoepithelial cells and showed that solitary myoepithelial cell could be seen in both benign and malignant lesions. They also noted that paired myoepithelial cells were a feature of only benign lesions which were absent in malignant lesions (58). The number of myoepithelial cells may be helpful in distinguishing between PBD versus DCIS and invasive carcinoma on fine needle aspiration cytology (FNAC) smears which is a useful tool for rapid and accurate diagnosis of various benign and malignant breast lesions with high sensitivity and specificity (65). Finally, the analysis of myoepithelial marker expression remains a commonly used approach to distinguish between benign and malignant tumors, or to detect stromal invasion. Therefore, early detection of the myoepithelial cell layer disruption may help in the identification of the status of breast carcinoma to select the patients for optimal treatment.
6. DISCUSSION AND CONCLUSION
Myoepithelial cells are present in almost all glandular organs; however, the exact role of these cells in tumor progression is yet to be clarified. It is believed that myoepithelial cells present in mammary glands have a role in the secretion of milk and in the synthesis of the basement membrane (1). The contractile function of the myoepithelial cells are always taken into account; however, it is now clear that myoepithelial cells are also important in some other physiological functions like regulation of growth, differentiation and morphogenesis of neighboring cells as they also secrete growth factors and cytokines such as basic fibroblast growth factor (bFGF), transforming growth factor-alpha (TGF-alpha) and various cytokines (2, 5, 11). The growth and development of tumors are determined not only by the specific oncogene activation or by the loss of tumor suppressor but also by some microenvironment factors that play important roles. The interaction of the secreted factors of the myoepithelial cells with the surrounding epithelial cells results in the promotion of proliferation of the endothelial cells and following angiogenesis which also increases the invasiveness of the tumor cells and helps in the metastatic spread (3, 5). It is now evident that myoepithelial cells have a role in stromal tumor invasion by secretion of various molecules resulting in degradation of BM, hypoxia and inflammation; however, many questions still remain unanswered like what are the exact mechanisms of the degradation of the myoepithelial cell layer? Why is there the overproduction of the degrading enzymes and other molecules? It is likely that the tumor cells can induce the myoepithelial cells to produce the degradative enzymes or the tumor cells themselves produce such molecules and enzymes.
Another important factor which may play a role in the breast tumor progression is the extracellular acidic pH of the tumor microenvironment which both the hypotheses failed to mention. Cancer cells proliferate rapidly and develop an acidic extracellular environment, which is believed to occur as a result of lactic acid accumulation produced during aerobic and anaerobic glycolysis. Several studies have indicated that cancer cells exposed to acidic pH in vitro may show increased expression of several genes known to promote invasive growth and metastasis, including genes encoding MMPs (MMP-2 and MMP-9), cysteine proteases like cathespin B and cathespin L. Several proangiogenic factors such as vascular endothelial growth factor-A (VEGF-A) and interleukin-8 (IL-8) are also induced due to acidity of the microenvironment (66, 67). It is possible that the myoepithelial cells present in the DCIS can also secrete these BM degrading and proangiogenic factors because of the acidic pH of the microenvironment. However, it is not clear whether this acidity-induced increase in gene expression is sufficient to enhance the metastatic potential of tumor cells. Rofstad et al., measured the secretion of these acidity-induced proteins in A-07, D-12 and T-22 human melanoma cells, cultured in acidic and normal medium and investigated whether treatment with proteinese inhibitors or neutralizing antibodies could inhibit acidity-induced invasiveness, angiogenesis and experimental metastasis. Their results showed that acidity indeed induced up-regulation of VEGF-A, IL-8, MMP-2, MMP-9, cathespin B and cathespin L resulting in the enhanced metastatic potential of these human melanoma cell lines thus providing significant evidence that acidity-induced up-regulation of these proteins is a possible mechanism for tumor invasiveness in melanoma cancer (68). This acidity-induced tumor invasiveness may also hold true for the tumor progression from DCIS to stroma but much works need to be done before coming to any conclusion.
Man et al. reported that the immunoreactive cells such as leucocytes and macrophages can produce MMPs when they come in contact with the damaged myoepithelial cells (4, 7). Another important question is how genetic abnormalities in the myoepithelial cells affect the secretion of these molecules? It is also possible that the secretions of the myoepithelial cells result in the degradation of their own however; no conclusive evidence has shown that host's own enzymes are capable of degrading its own myoepithelial cells. Are there any preventive mechanisms for this myoepithelial cell layer not to be degraded? Are there any factors and molecules that play significant roles in this mechanism? The role of other signaling pathways in over-production of proteolytic enzymes is also not clearly understood. Do the tumor cells have the ability to induce the myoepithelial cells to secrete these degrading enzymes and other angiogenesis factors so that the tumor cells can exploit it for their own benefits? The identification of disruption of myoepithelial cells beforehand may have a clinical significance (60-65). This will make the prognosis of breast cancer easier but the question is how we can properly identify the early disruption of myoepithelial cells. There is an urgent need for some rapid and sensitive method for the detection of degraded myoepithelial cells. Several markers have been reported for the immunohistochemical detection of breast myoepithelial cells and their correct recognition and detection may serve as tools for the diagnosis of breast cancers although the sensitivity and specificity of these markers vary widely (5, 6). Maspin and p63 are most promising at this time and the identification of more sensitive and specific markers is necessary for the prompt and proper diagnosis of breast lesions.
The fact that myoepithelial cells constitutively express a large amount of tumor suppressors, proteinase inhibitors and angiogenesis inhibitors has changed the way we look at the myoepithelial cells (9, 11). It is also clear now that cancer cells come under the influence of important paracrine regulation from the host microenvironment (4, 7). Therefore, it seems that myoepithelial cells have an important role in the paracrine regulation of the normal and tumor cells present in the microenvironment; however the precise mechanism of these molecules in the suppression of tumor progression and how these functions are compromised during cancer development are yet to be clarified.
In conclusion, the potential role of myoepithelial cells in tumor progression has always been under-recognized; however, it is now believed that myoepithelial cells have an important regulatory role in breast cancer by influencing the epithelial and luminal compartments and ultimately altering the tissue microenvironment. Myoepithelial cells appear to have dual functions as tumor suppressor and promoter. However much remains to be learned about the molecular mechanism and physiological role of myoepithelial cells in the tumor invasion and metastasis, which may eventually lead to the development of novel approaches for the prevention and treatment of breast cancer.
7. REFERENCES
1. Priori SG, Aliot E, Blømstrom-Lundqvist C, Bossaert L, Breithardt G, Brugada P, Camm JA, Cappato R, Cobbe SM, Di MC, Maron BJ, McKenna WJ, Pedersen AK, Ravens U, Schwartz PJ, Trusz-Gluza M, Vardas P, Wellens HJ, Zipes DP. Task Force on Sudden Cardiac Death, European Society of Cardiology. Europace, 4:3-18 (2002)
doi:10.1053/eupc.2001.0214
PMid:11858152
2. Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J, 18:1231-48 (1997)
3. American Heart Association. Heart disease and stroke statistics. Dallas, TX: American Heart Association. (2005)
4. Atwood C, Eisenberg MS, Herlitz J, Rea TD. Incidence of EMS-treated out-of-hospital cardiac arrest in Europe. Resuscitation, 67:75-80 (2005)
doi:10.1016/j.resuscitation.2005.03.021
PMid:16199289
5. Edgren E, Kelsey S, Sulton K, Safar P. The presenting ECG pattern in survivors of cardiac arrest and its relation to subsequent long-term survival. Brain Resuscitation Clinical Trial I Study Group. Acta Anaesthesiol Scand, 33:265-71 (1989)
doi:10.1111/j.1399-6576.1989.tb02905.x
PMid:2655364
6. American Heart Association 2005 Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation, 112:IV-1-IV-203 (2005)
doi:10.1161/CIRCULATIONAHA.105.166550
7. Becker LB, Ostrander MP, Barrett J, Kondos GT. CPR Chicago: outcome of cardiopulmonary resuscitation in a large metropolitan area - where are the survivors? Ann Emerg Med, 20:355-361 (1991)
doi:10.1016/S0196-0644(05)81654-3
PMid:2003661
8. Brain Resuscitation Clinical Trial II Study Group: A randomized clinical study of a calcium-entry blocker (lidoflazine) in the treatment of comatose survivors of cardiac arrest. N Engl J Med, 324:1125-1231 (1991)
9. Brown CG, Martin DR, Pepe PE. A comparison of standard-dose and high-dose epinephrine in cardiac arrest outside the hospital. N Engl J Med, 327:1051-1055 (1992)
10. Lombardi G, Gallagher J, Gennis P. Outcome of out-of-hospital cardiac arrest in New York City: the Pre-hospital Arrest Survival Evaluation (PHASE) study. JAMA, 271:678-683 (1994)
doi:10.1001/jama.271.9.678
PMid:8309030
11. Stiell IG, Herbert PC, Weitzman BN. High-dose epinephrine in adult cardiac arrest. N Engl J Med, 327:1045-1050 (1992)
12. Adrie C, Laurent I, Monchi M, Cariou A, Dhainaou JF, Spaulding C. Postresuscitation disease after cardiac arrest: a sepsis-like syndrome? Curr Opin Crit Care, 10:208-212 (2004)
doi:10.1097/01.ccx.0000126090.06275.fe
PMid:15166838
13. DeBard ML. Cardiopulmonary resuscitation: analysis of six years' experience and review of the literature. Ann Emerg Med, 10:408-416 (1981)
doi:10.1016/S0196-0644(81)80307-1
PMid:7258755
14. Peatfield RC, Sillett RW, Taylor D, McNicol MW. Survival after cardiac arrest in the hospital. Lancet, 1:1223-1225 (1977)
doi:10.1016/S0140-6736(77)92435-7
15. Tang W, Weil MH, Sun SJ, Gazmuri RJ, Bisera J, Rackow EC. Progressive myocardial dysfunction after cardiac resuscitation. Crit Care Med, 21:1046-1050 (1993)
doi:10.1097/00003246-199307000-00022
PMid:8319463
16. Eisenberg MS, Horwood BT, Cummins RO, Reynolds-Haertle R, Hearne TR. Cardiac arrest and resuscitation: a tale of 29 cities. Ann Emerg Med 19:179-186, (1990)
doi:10.1016/S0196-0644(05)81805-0
PMid:2301797
17. Safar P. Cerebral resuscitation after cardiac arrest: research initiatives and future directions. Ann Emerg Med, 22:324-349 (1993)
doi:10.1016/S0196-0644(05)80463-9
PMid:8434832
18. Böttiger BW, Grabner C, Bauer H, Bode C, Weber T, Motsch J, Martin E. Long term outcome after out-of-hospital cardiac arrest with physician staffed emergency medical services: the Utstein style applied to a midsized urban/suburban area. Heart, 82:674-679 (1999)
19. Stiell IG, Wells GA, Field B, Spaite DW, Nesbitt LP, De Maio VJ, Nichol G, Cousineau D, Blackburn J, Munkley D, Luinstra-Toohey L, Campeau T, Dagnone E, Lyver M; Ontario Prehospital Advanced Life Support Study Group. Advanced cardiac life support in out-of-hospital cardiac arrest. N Engl J Med, 351:647-656 (2004)
doi:10.1056/NEJMoa040325
PMid:15306666
20. Ma MH, Chiang WC, Ko PC, Huang JC, Lin CH, Wang HC, Chang WT, Hwang CH, Wang YC, Hsiung GH, Lee BC, Chen SC, Chen WJ, Lin FY. Outcomes from out-of-hospital cardiac arrest in Metropolitan Taipei: does an advanced life support service make a difference? Resuscitation, 74:461-469 (2007)
doi:10.1016/j.resuscitation.2007.02.006
PMid:17462809
21. Werling M, Thoren AB, Axelsson C, Herlitz J. Treatment and outcome in postresuscitation care after out-of-hospital cardiac arrest when a modern therapeutic approach was introduced. Resuscitation, 73:40-45 (2007)
doi:10.1016/j.resuscitation.2006.08.018
PMid:17241730
22. Fairbanks RJ, Shah MN, Lerner EB, Ilangovan K, Pennington EC, Schneider SM. Epidemiology and outcomes of out-of-hospital cardiac arrest in Rochester, New York. Resuscitation, 72:415-424 (2007)
doi:10.1016/j.resuscitation.2006.06.135
PMid:17174021
23. Bernard S: Outcome from prehospital cardiac arrest in Melbourne, Australia. Emerg Med, 10:25-29 (1998)
24. Edgren E, Hedstrand U, Kelsey S, Sutton-Tyrrell K, Safar P. Assessment of neurological prognosis in comatose survivors of cardiac arrest. BRCT I Study Group. Lancet, 343:1055-1059 (1994)
doi:10.1016/S0140-6736(94)90179-1
25. Engdahl J, Abrahamsson P, Bang A, Lindqvist J, Karlsson T, Herlitz J. Is hospital care of major importance for outcome after out-of-hospital cardiac arrest? Experience acquired from patients with out-of-hospital cardiac arrest resuscitated by the same Emergency Medical Service and admitted to one of two hospitals over a 16-year period in the municipality of Goteborg. Resuscitation, 43(3):201-211 (2000)
doi:10.1016/S0300-9572(99)00154-9
PMid:10711489
26. Cooper S, Cade J. Predicting survival, in-hospital cardiac arrests: resuscitation survival variables and training effectiveness. Resuscitation, 35:17-22 (1997)
doi:10.1016/S0300-9572(97)00020-8
PMid:9259055
27. Hallstrom AP, Cobb LA, Yu BH. Influence of co-morbidity on the outcome of patients treated for out-of-hospital ventricular fibrillation. Circulation, 93:2019-22 (1996)
28. Herlitz J, Ekstrom L, Wennerblom B, Axelsson A, Bång A, Holmberg S. Predictors of early and late survival after out-of-hospital cardiac arrest in which asystole was the first recorded arrhythmia on scene. Resuscitation, 28:27-36 (1994)
doi:10.1016/0300-9572(94)90051-5
PMid:7809482
29. Ewy GA. Cardiopulmonary resuscitation: strengthening the links in the chain of survival. N Engl J Med, 342: 1599-601 (2000)
doi:10.1056/NEJM200005253422109
PMid:10824080
30. Berek K, Lechleitner P, Luef G, Felber S, Saltuari L, Schinnerl A, Traweger C, Dienstl F, Aichner F. Early determination of neurological outcome after prehospital cardiopulmonary resuscitation. Stroke, 26:543-9 (1995)
31. Jorgensen EO, Holm S. The course of circulatory and cerebral recovery after circulatory arrest: influence of prearrest, arrest and post-arrest factors. Resuscitation, 42:173-82 (1999)
doi:10.1016/S0300-9572(99)00116-1
PMid:10625157
32. Cummins RO, Ornato JP, Thies WH, Pepe PE. Improving survival from sudden cardiac arrest: the 'chain of survival' concept. A statement for health professionals from the Advanced Cardiac Life Support Subcommittee and the Emergency Cardiac Care Committee, American Heart Association. Circulation, 83:1832-1847 (1991)
33. Negovsky VA. The second step in resuscitation-the treatment of the 'postresuscitation disease'. Resuscitation, 1:1-7 (1972)
doi:10.1016/0300-9572(72)90058-5
PMid:4653025
34. Nolan JP, Deakin CD, Soar J. European Resuscitation Council guidelines for resuscitation 2005. Section 4. Adult advanced life support. Resuscitation, 67:S39-S86 (2005)
doi:10.1016/j.resuscitation.2005.10.009
PMid:16321716
35. Negovsky VA. Postresuscitation disease. Crit Care Med, 16:942-6 (1988)
doi:10.1097/00003246-198810000-00004
PMid:3048895
36. Negovsky VA, Gurvitch AM. Post-resuscitation disease - a new nosological entity. Its reality and significance. Resuscitation, 30:23-7 (1995)
doi:10.1016/0300-9572(95)00861-M
PMid:7481099
37. Nolan JP, Neumar RW, Adrie C, Aibiki M, Berg RA, Böttiger BW, Callaway C, Clark RSB, Geocadin RG, Jauch EC, Kern KB, Laurent I, Longstreth WT, Merchant RM, Morley P, Morrison LJ, Nadkarni V, Peberdy MA, Rivers EP,Rodriguez-Nunez A, Sellke FW, Spaulding C, Sunde K, Vanden Hoek T. ILCOR CONSENSUS STATEMENT. Post-cardiac arrest syndrome: Epidemiology, pathophysiology, treatment, and prognostication. A Scientific Statement from the International Liaison Committee on Resuscitation; the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; the Council on Stroke. Resuscitation, 79:350-379 (2008)
doi:10.1016/j.resuscitation.2008.09.017
PMid:18963350
38. Zandbergen EG, de Haan RJ, Stoutenbeek CP, Koelman JH, Hijdra A. Systematic review of early prediction of poor outcome in anoxic-ischemic coma. Lancet, 352:1808-12 (1998)
doi:10.1016/S0140-6736(98)04076-8
39. Zandbergen EGJ, de Haan RJ, Hijdra A. Systematic review of prediction of poor outcome in anoxic-ischaemic coma with biochemical markers of brain damage. Intensive Care Med, 27:1661-67 (2001)
doi:10.1007/s001340101076
PMid:11685309
40. Wijdicks EFM, Hijdra A, Young GB, Bassetti CL,Wiebe S. Practice parameter: prediction of outcome in comatose survivors after cardiopulmonary resuscitation (an evidence-based review). Neurology, 67:203-210 (2006)
doi:10.1212/01.wnl.0000227183.21314.cd
PMid:16864809
41. E. Al Thenayan, M. Savard, M. Sharpe, L. Norton, B. Young. Predictors of poor neurologic outcome after induced mild hypothermia following cardiac arrest. Neurology, 71:1535-37 (2008)
doi:10.1212/01.wnl.0000334205.81148.31
PMid:18981375
42. Weir RF, Gostin L. Decisions to abate life-sustaining treatment for nonautonomous patients. Ethical standards and legal liability for physicians after Cruzan. JAMA, 264:1846-53 (1990)
doi:10.1001/jama.264.14.1846
PMid:2402044
43. Persistent vegetative state and the decision to withdraw or withhold life support. Council on Scientific Affairs and Council on Ethical and Judicial Affairs. JAMA, 263:426-30 (1990)
doi:10.1001/jama.263.3.426
PMid:2403610
44. Medical futility in end-of-life care: report of the Council on Ethical and Judicial Affairs. JAMA, 281:937-41 (1999)
doi:10.1001/jama.281.10.937
PMid:10078492
45. Position of the American Academy of Neurology on certain aspects of the care and management of the persistent vegetative state patient. Adopted by the Executive Board, American Academy of Neurology; 21 April 1988; Cincinnati, OH. Neurology 39:125-26 (1989)
46. Ethical and moral guidelines for the initiation, continuation, and withdrawal of intensive care. American College of Chest Physicians/Society of Critical Care Medicine Consensus Panel. Chest, 97:949-58 (1990)
doi:10.1378/chest.97.4.949
PMid:2182302
47. Martens P, Haymerle A, Sterz F, Vanhaute O, Calle P. Limitation of life support after resuscitation from cardiac arrest: practice in Belgium and Austria. Resuscitation, 35(2):123-8 (1997)
doi:10.1016/S0300-9572(97)00037-3
PMid:9316195
48. Jacobs P, Noseworthy TW. National estimates of intensive care utilization and costs: Canada and the United States. Crit Care Med, 18(11):1282-6 (1990)
doi:10.1097/00003246-199011000-00020
PMid:2225900
49. Alvarez-Diaz A, Hilario E, de Cerio FG, Soler A Alvarez-Diaz FJ. Hypoxic-ischemic injury in the immature brain-key vascular and cellular players. Neonatology, 92:227 (2007)
doi:10.1159/000103741
PMid:17556841
50. Walton M, Connor B, Lawlor P, Young D, Sirimanne E, Gluckman P, Cole, G, Dragunow M. Neuronal death and survival in two models of hypoxic-ischemic brain damage. Brain Res Brain Res Rev, 29:137 (1999)
doi:10.1016/S0165-0173(98)00053-8
PMid:10209230
51. Ferriero DM. Neonatal brain injury. N Engl J Med, 351(19):1985-95 (2004)
doi:10.1056/NEJMra041996
52. Sugawara T, Fujimura M, Noshita N, Kim GW, Saito A, Hayashi T, Narasimhan P, Maier CM, Chan PH. Neuronal death/survival signaling pathways in cerebral ischemia. NeuroRx, 1:17 (2004)
doi:10.1602/neurorx.1.1.17
53. Volpe JJ. Brain injury in the premature infant: overview of clinical aspects, neuropathology, and pathogenesis. Semin. Pediatr Neurol, 5, 135 (1998)
doi:10.1016/S1071-9091(98)80030-2
54. Lorek A, Takei Y, Cady EB, Wyatt JS, Penrice J, Edwards AD, Peebles D, Wylezinska M, Owen-Reece H, Kirkbride V. Delayed ("secondary") cerebral energy failure after acute hypoxiaischemia in the newborn piglet: continuous 48-hour studies by phosphorus magnetic resonance spectroscopy. Pediatr Res, 36:699 (1994)
doi:10.1203/00006450-199412000-00003
55. Back SA, Luo NL, Borenstein NS, Levine JM, Volpe JJ, Kinney HC. Late oligodendrocyte progenitors coincide with the developmental window of vulnerability for human perinatal white matter injury. J. Neurosci. 21:1302 (2001)
56. Hilario E, Rey-Santano MC, Goni-de-Cerio F, Alvarez FJ, Gastiasoro E, Mielgo VE, Caballero A, Soler A, Gomez- Urquijo S, Alvarez A. Cerebral blood flow and morphological changes after hypoxic-ischaemic injury in preterm lambs. Acta Paediatr, 94:903 (2005)
doi:10.1080/08035250510031151
57. Volpe JJ. Brain injury in the premature infant--current concepts. Prev Med, 23:638 (1994)
doi:10.1006/pmed.1994.1106
58. Volpe JJ. Neurobiology of periventricular leukomalacia in the premature infant. Pediatr Res, 50:553 (2001)
doi:10.1203/00006450-200111000-00003
59. du Plessis, AJ, Volpe JJ Perinatal brain injury in the preterm and term newborn. Curr Opin Neurol, 15:151 (2002)
doi:10.1097/00019052-200204000-00005
60. Berger R. Garnier Y. Perinatal brain injury. J Perinat Med, 28:261 (2000)
doi:10.1515/JPM.2000.034
61. Johnston MV, Trescher WH, Ishida A, Nakajima W. Neurobiology of hypoxic-ischemic injury in the developing brain. Pediatr Res, 49:735 (2001)
doi:10.1203/00006450-200106000-00003
62. Halterman MW, Miller CC, Federoff HJ. Hypoxia-inducible factor-1alpha mediates hypoxia-induced delayed neuronal death that involves p53. J Neurosci, 19:6818 (1999)
63. Droge W. Free radicals in the physiological control of cell function. Physiol Rev, 82:47 (2002)
64. Jensen A, Garnier Y, Middelanis J, Berger R. Perinatal brain damage: from pathophysiology to prevention. Eur J Obstet Gynecol Reprod Biol, 110(Suppl. 1), S70-9 (2003)
doi:10.1016/S0301-2115(03)00175-1
65. Buonocore G, Perrone S. Biomarkers of hypoxic brain injury in the neonate. Clin Perinatol, 31:107 (2004)
doi:10.1016/j.clp.2004.03.008
66. Fern R, Moller T. Rapid ischemic cell death in immature oligodendrocytes: a fatal glutamate release feedback loop. J Neurosci, 20:34 (2000)
67. Palmer C, Towfighi J, Roberts RL, Heitjan DF. Allopurinol administered after inducing hypoxia-ischemia reduces brain injury in 7-day-old rats. Pediatr Res, 33:405 (1993)
68. Hamada Y, Hayakawa T, Hattori H, Mikawa H. Inhibitor of nitric oxide synthesis reduces hypoxic-ischemic brain damage in the neonatal rat. Pediatr Res, 35:10 (1994)
doi:10.1203/00006450-199401000-00003
69. Patkai J, Mesples B, Dommergues MA, Fromont G, Thornton EM, Renauld JC, Evrard P, Gressens P. Deleterious effects of IL-9-activated mast cells and neuroprotection by antihistamine drugs in the developing mouse brain. Pediatr Res, 50:222 (2001)
doi:10.1203/00006450-200108000-00010
70. Kristian, T. Metabolic stages, mitochondria and calcium in hypoxic/ischemic brain damage. Cell Calcium, 36:221 (2004)
doi:10.1016/j.ceca.2004.02.016
71. Hossmann KA. Ischemia-mediated neuronal injury. Resuscitation, 26:225-35 (1993)
doi:10.1016/0300-9572(93)90143-E
72. Smith ML, Auer RN, Siesjö BK. The density and distribution of ischemic brain injury in the rat following 2-10 min of forebrain ischemia. Acta Neuropathol (Berl), 64:319-32 (1984)
doi:10.1007/BF00690397
73. Horn M, Schlote W. Delayed neuronal death and delayed neuronal recovery in the human brain following global ischemia. Acta Neuropathol Berl 85:79-87 (1992)
doi:10.1007/BF00304636
74. Pulsinelli W, Brierly JB, Plum F. Temporal profile of neuronal damage in a model of transient forebrain ischemia. Ann Neurol 11:491-498 (1982)
doi:10.1002/ana.410110509
75. Böttiger BW, Schmitz B, Wiessner C, Vogel P, Hossmann KA. Neuronal stress response and neuronal cell damage after cardiocirculatory arrest in rats. J Cereb Blood Flow Metab, 18(10):1077-87 (1998)
doi:10.1097/00004647-199810000-00004
76. Liachenko S, Tang P, Hamilton RL, Xu Y. Regional dependence of cerebral reperfusion after circulatory arrest in rats. J Cereb Blood Flow, 21:1320-9 (2001)
doi:10.1097/00004647-200111000-00008
77. Bottiger BW, Krumnikl JJ, Gass P, Schmitz B, Motsch J, Martin E. The cerebral 'no-reflow' phenomenon after cardiac arrest in rats - influence of low-flow reperfusion. Resuscitation, 34:79-87 (1997)
doi:10.1016/S0300-9572(96)01029-5
78. Hossmann KA. Ischemia-mediated neuronal injury. Resuscitation, 26:225-35 (1993)
doi:10.1016/0300-9572(93)90143-E
79. Fischer M, Hossmann KA. No-reflow after cardiac arrest. Intensive Care Med, 21:132-41 (1995)
doi:10.1007/BF01726536
80. Ristagno G, Tang W, Sun S, Weil MH. Cerebral cortical microvascular flow during and following cardiopulmonary resuscitation after short duration of cardiac arrest. Resuscitation, 77:229-234 (2008)
doi:10.1016/j.resuscitation.2007.12.013
81. Kuroiwa T, Bonnekoh P, Hossmann KA. Therapeutic window of CA1 neuronal damage defined by an ultrashort-acting barbiturate after brain ischemia in gerbils. Stroke, 21:1489-1493 (1990)
82. Kirino T. Delayed neuronal death in the gerbil hippocampus following ischemia. Brain Res, 239:57-69 (1982)
doi:10.1016/0006-8993(82)90833-2
83. Kirino T, Sano K. Selective vulnerability in the gerbil hippocampus following transient ischemia. Acta Neuropathol (Berl), 62:201-208 (1984)
doi:10.1007/BF00691853
84. Petito CK, Pulsinelli WA. Delayed neuronal recovery and neuronal death in rat hippocampus following severe cerebral ischemia: possible relationship to abnormalities in neuronal processes. J Cereb Blood Flow Metab, 4:194-205 (1984)
85. Kirino T, Tamura A, Sano K. Selective vulnerability of the hippocampus to ischemia: reversible and irreversible types of ischemic cell damage. Prog Brain Res, 63:39-58 (1985)
doi:10.1016/S0079-6123(08)61974-3
86. Pulsinelli WA, Duffy TE. Regional energy balance in rat brain after transient forebrain ischemia. J Neurochem, 40:1500-1503 (1983)
87. Markus Horn, MD; Florian Seger, MD Wolfgang Schlote, MD. Neuron-Specific Enolase in Gerbil Brain and Serum After Transient Cerebral Ischemia. Stroke, 26:290-297 (1995)
88. Barone FC, Clark RK, Price WJ, White RF, Feuerstein GZ, Storer BL, Ohlstein EH. Neuron-specific enolase increases in cerebral and systemic circulation following focal ischemia. Brain Res, 24;623(1):77-82 (1993)
89. Krieter H, Denz C, Janke C, Bertsch T, Luiz T, Ellinger K, van Ackern K. Hypertonic-Hyperoncotic Solutions Reduce the Release of Cardiac Troponin I and S-100 After Successful Cardiopulmonary Resuscitation in Pigs. Anesth Analg, 95:1031-1036 (2002)
doi:10.1097/00000539-200210000-00044
90. Sirin BH, Coşkun E, Yilik L, Ortaç R, Sirin H, Tetik C. Neuroprotective effects of preischemia subcutaneous magnesium sulfate in transient cerebral ischemia. Eur J Cardiothorac Surg, 14(1): 82-8 (1998)
doi:10.1016/S1010-7940(98)00140-7
91. Shirasaki Y, Edo N and Sato T. Serum S-100b protein as a biomarker for the assessment of neuroprotectants. Brain Res, 24;1021(2):159-166 (2004)
92. Kecskes Z, Dunster KR, Colditz PB. NSE and S100 after Hypoxia in the Newborn Pig. Pediatric Research, 58:5; 953-957 (2005)
doi:10.1203/01.PDR.0000182591.46087.7D
93. Kiessling M, Dienel GA, Jacewicz M, Pulsinelli WA. Protein synthesis in postischemic rat brain: a two-dimensional electrophoretic analysis. J Cereb Blood Flow Metab, 6:642-649 (1986)
94. Pokela M, Anttila V, Rimpiläinen J, Hirvonen J, Vainionpää V, Kiviluoma K, Romsi P, Mennander A, Juvonen T. Serum S-100beta protein predicts brain injury after hypothermic circulatory arrest in pigs. Scand Cardiovasc J, 34(6):570-4 (2000)
doi:10.1080/140174300750064495
95. Hårdemark HG, Ericsson N, Kotwica Z, Rundström G, Mendel-Hartvig I, Olsson Y, Påhlman S, Persson L. S-100 protein and neuron-specific enolase in CSF after experimental traumatic or focal ischemic brain damage. J Neurosurg, 71(5 Pt 1):727-31 (1989)
doi:10.3171/jns.1989.71.5.0727
96. Steinberg R, Gueniau C, Scarna H, Keller A, Worcel M, Pujol JF. Experimental brain ischemia: neuron-specific enolase level in cerebrospinal fluid as an index of neuronal damage. J Neurochem, 43(1):19-24 (1984)
doi:10.1111/j.1471-4159.1984.tb06673.x
97. Hardemark HG, Persson L, Bolander HG, Hillered L, Olsson Y, Pahlman S. Neuron-specific enolase is a marker of cerebral ischemia and infarct size in rat cerebrospinal fluid. Stroke, 19(9):1140-4 (1988)
98. Guilherme S. Mazzinia, Débora V. Schafa, Álvaro R. Oliveirab, Carlos A. Gonçalvesa, Adriane Belló-Kleinc, Solange Bordignond, Ricardo S. Bruchd, Guilherme F. Camposa, Dalton V. Vassalloe, Diogo O. Souzaa and Luis V.C. Portela. The ischemic rat heart releases S100B. Life Sciences, 77(8):882-89 (2005)
99. Alam HB, Chen Z, Ahuja N, Chen H, Conran R, Ayuste EC, Toruno K, Ariaban N, Rhee P, Nadel A, Koustova E. Profound hypothermia protects neurons and astrocytes, and preserves cognitive functions in a Swine model of lethal hemorrhage. J Surg Res, 15;126(2):172-81 (2005)
100. Usui A, Kato K, Murase M, Hotta T, Tanaka M, Takeuchi E, Abe T. Neural tissue-related proteins (NSE, G0 alpha, 28-kDa calbindin-D, S100b and CK-BB) in serum and cerebrospinal fluid after cardiac arrest. J Neurol Sci, 123(1-2):134-9 (1994)
doi:10.1016/0022-510X(94)90215-1
101. Fries M, Nolte KW, Coburn M, Rex S, Timper A, Kottmann K, Siepmann K, Häusler M, Weis J, Rossaint R. Xenon reduces neurohistopathological damage and improves the early neurological deficit after cardiac arrest in pigs. Crit Care Med, 36:2420-6 (2008)
doi:10.1097/CCM.0b013e3181802874
PMid:18664790
102. Kanner AA, Marchi N, Fazio V, Mayberg MR, Koltz MT, Siomin V, Stevens GH, Masaryk T, Aumayr B, Vogelbaum MA, Barnett GH, Janigro D. Serum S100beta: a noninvasive marker of blood-brain barrier function and brain lesions. Cancer, 97:2806-13 (2003)
doi:10.1002/cncr.11409
PMid:12767094
103. Bassetti C, Bomio F, Mathis J, Hess CW. Early prognosis in coma after cardiac arrest: a prospective clinical, electrophysiological, and biochemical study of 60 patients. J Neurol Neurosurg Psychiatry, 61:610-15 (1996)
doi:10.1136/jnnp.61.6.610
104. Levy DE, Caronna JJ, Singer BH, Lapinski RH, Frydman H, Plum F. Predicting outcome from hypoxic-ischemic coma. JAMA, 253:1420-6 (1985)
doi:10.1001/jama.253.10.1420
PMid:3968772
105. Madl C, Grimm G, Kramer L, Yeganehfar W, Sterz F, Schneider B, Kranz A, Schneeweiss B, Lenz K. Early prediction of individual outcome after cardiopulmonary resuscitation. Lancet, 341:855-8 (1993)
doi:10.1016/0140-6736(93)93061-5
106. Mullie A, Verstringe P, Buylaert W, Houbrechts H, Michem N, Delooz H, Verbruggen H, Van den Broeck L, Corne L, Lauwaert D, et al. Predictive value of Glasgow Coma Score for awakening after out-of-hospital cardiac arrest. Cerebral Resuscitation Study Group of the Belgian Society for Intensive Care. Lancet, 1:137-40 (1988)
107. Saltuari L, Marosi M. Coma after cardiac arrest: will he recover all right? Lancet, 343:1052-3 (1994)
doi:10.1016/S0140-6736(94)90176-7
108. Fujioka M, Okuchi K, Sakaki T, Hiramatsu K, Miyamoto S, Iwasaki S: Specific changes in human brain following reperfusion after cardiac arrest. Stroke, 25:2091-95 (1994)
109. Morimoto Y, Kemmotsu O, Kitami K, Matsubara I, Tedo I. Acute brain swelling after out-of-hospital cardiac arrest: Pathogenesis and outcome. Crit Care Med, 21:104-10 (1993)
doi:10.1097/00003246-199301000-00020
PMid:8420715
110. Rothstein TL. The role of evoked potentials in anoxic-ischemic coma and severe brain trauma. J Clin Neurophysiol, 17(5):486-497 (2000)
doi:10.1097/00004691-200009000-00007
PMid:11085552
111. Bottiger BW, Mobes S, Glatzer R, Bauer H, Gries A, Bärtsch P, Motsch J, Martin E. Astroglial protein S-100 is an early and sensitive marker of hypoxic brain damage and outcome after cardiac arrest in humans. Circulation, 103:2694-98 (2001)
112. Fogel W, Krieger D, Veith M, Adams HP, Hund E, Storch-Hagenlocher B, Buggle F, Mathias D, Hacke W. Serum neuron-specific enolase as early predictor of outcome after cardiac arrest. Crit Care Med, 25:1133-38 (1997)
doi:10.1097/00003246-199707000-00012
PMid:9233737
113. Grubb NR, Simpson C, Sherwood R, Abraha HD, Cobbe SM, O'Carroll RE, Deary I, Fox KA. Prediction of cognitive dysfunction after resuscitation from out-of-hospital cardiac arrest using serum neuronspecific enolase and protein S-100. Heart, 93:1268-73 (2007)
doi:10.1136/hrt.2006.091314
PMid:17502328
114. Mussack T, Biberthaler P, Kanz KG, Wiedemann E, Gippner-Steppert C, Mutschler W, Jochum M. Serum S-100B and interleukin-8 as predictive markers for comparative neurologic outcome analysis of patients after cardiac arrest and severe traumatic brain injury. Crit Care Med, 30:2669-74 (2002)
doi:10.1097/00003246-200212000-00010
PMid:12483057
115. Tiainen M, Roine RO, Pettila V, Takkunen O. Serum neuron-specific enolase and S-100B protein in cardiac arrest patients treated with hypothermia. Stroke, 34:2881-86 (2003)
doi:10.1161/01.STR.0000103320.90706.35
PMid:14631087
116. Meynaar IA, Oudemans-van Straaten HM, van der Wetering J, Verlooy P, Slaats EH, Bosman RJ, van der Spoel JI, Zandstra DF. Serum neuron-specific enolase predicts outcome in postanoxic coma: a prospective cohort study. Intensive Care Med, 29:189-95 (2003)
117. Sekido N, Mukaida N, Harada A, Nakanishi I, Watanabe Y, Matsushima K. Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature, 365:654-7 (1993)
doi:10.1038/365654a0
PMid:8413628
118. Ito T, Saitoh D, Fukuzuka K, Kiyozumi T, Kawakami M, Sakamoto T, Okada Y. Significance of elevated serum interleukin-8 in patients resuscitated after cardiopulmonary arrest. Resuscitation, 51:47-53 (2001)
doi:10.1016/S0300-9572(01)00382-3
PMid:11719173
119. Tirschwell DL, Longstreth WT Jr, Rauch-Matthews ME, Chandler WL, Rothstein T, Wray L, Eng LJ, Fine J, Copass MK. Cerebrospinal fluid creatine kinase BB isoenzyme activity and neurologic prognosis after cardiac arrest. Neurology, 48:352-357 (1997)
120. Sherman AL, Tirschwell DL, Micklesen PJ, Longstreth WT Jr, Robinson LR. Somatosensory potentials, CSF creatine kinase- BB activity, and awakening after cardiac arrest. Neurology, 54:889-94 (2000)
121. Kärkelä J, Pasanen M, Kaukinen S, Mörsky P, Harmoinen A. Evaluation of hypoxic brain injury with spinal fluid enzymes, lactate, and pyruvate. Crit Care Med, 20(3):378-86 (1992)
122. Kärkelä J, Bock E, Kaukinen S. CSF and serum brain-specific creatine kinase isoenzyme (CK-BB), neuron-specific enolase (NSE) and neural cell adhesion molecule (NCAM) as prognostic markers for hypoxic brain injury after cardiac arrest in man. J Neurol Sci, 116(1):100-9 (1993)
doi:10.1016/0022-510X(93)90095-G
PMid:8509798
123. Kjekshus JK, Vaagenes P, Hetland O. Assessment of cerebral injury with spinal fluid creatine kinase (CSF-CK) in patients after cardiac resuscitation. Scand J Clin Lab Invest, 40:437-444 (1980)
doi:10.3109/00365518009101866
PMid:7444346
124. Vaagenes P, Mullie A, Fodstad DT, Abramson N, Safar P. The use of cytosolic enzyme increase in cerebrospinal fluid of patients resuscitated after cardiac arrest. Brain Resuscitation Clinical Trial I Study Group. Am J Emerg Med, 12:621-4 (1994)
doi:10.1016/0735-6757(94)90026-4
PMid:7945601
125. Mussack T, Biberthaler P, Kanz KG, Wiedemann E, Gippner-Steppert C, Jochum M. S-100b, sE-selectin, and sP-selectin for evaluation of hypoxic brain damage in patients after cardiopulmonary resuscitation: pilot study. World J Surg, 25(5):539-43; discussion 544 (2001)
126. Gazzolo D, Abella R, Marinoni E, Di Iorio R, Li Volti G, Galvano F, Pongiglione G, Frigiola A, Bertino E, Florio P. Circulating biochemical markers of brain damage in infants complicated by ischemia reperfusion injury. Cardiovasc Hematol Agents Med Chem, 7(2):108-26 (2009)
doi:10.2174/187152509787847119
127. Falkensammer J, Oldenburg WA, Hendrzak AJ, Neuhauser B, Pedraza O, Ferman T, Klocker J, Biebl M, Hugl B, Meschia JF, Hakaim AG, Brott TG. Evaluation of subclinical cerebral injury and neuropsychologic function in patients undergoing carotid endarterectomy. Ann Vasc Surg, 22(4):497-504 (2008)
doi:10.1016/j.avsg.2008.01.013
PMid:18504102
128. Mussack T, Biberthaler P, Geisenberger T, Gippner-Steppert C, Steckmeier B, Mutschler W, Jochum M. Assessment of Early Brain Damage in Carotid Endarterectomy: Evaluation of S-100B Serum Levels and Somatosensory Evoked Potentials in a Pilot Study. World J Surg 26:1251-55 (2002)
doi:10.1007/s00268-002-6547-6
PMid:12205550
129. Raabe A, Grolms C, Keller M, Döhnert J, Sorge O, Seifert V. Correlation of computed tomography findings and serum brain damage markers following severe head injury. Acta Neurochir (Wien), 140:787-92 (1998)
doi:10.1007/s007010050180
PMid:9810445
130. Skogseid IM, Nordby HK, Urdal P, Paus E, Lilleaas F. Increased serum creatine kinase BB and neuron specific enolase following head injury indicates brain damage. Acta Neurochir (Wien), 115:106-11 (1992)
doi:10.1007/BF01406367
PMid:1605077
131. Woertgen C, Rothoerl RD, Holzschuh M, Metz C, Brawanski A. Comparison of serial S-100 and NSE serum measurements after severe head injury. Acta Neurochir (Wien), 139:1161-4 (1997)
doi:10.1007/BF01410977
PMid:9479423
132. Missler U, Wiesmann M, Friedrich C, Kaps M. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke, 28:1956-60 (1997)
133. Fassbender K, Schmidt R, Schreiner A, Fatar M, Mühlhauser F, Daffertshofer M, Hennerici M. Leakage of brain-originated proteins in peripheral blood: temporal profile and diagnostic value in early ischemic stroke. J Neurol Sci, 148:101-5 (1997)
doi:10.1016/S0022-510X(96)05351-8
PMid:9125396
134. Johnsson P, Lundqvist C, Lindgren A, Ferencz I, Alling C, Ståhl E. Cerebral complications after cardiac surgery assessed by S-100 and NSE levels in blood. J Cardiothorac Vasc Anesth, 9:694-9 (1995)
doi:10.1016/S1053-0770(05)80231-9
PMid:8664461
135. Westaby S, Johnsson P, Parry AJ, Blomqvist S, Solem JO, Alling C, Pillai R, Taggart DP, Grebenik C, Ståhl E. Serum S100 protein: a potential marker for cerebral events during cardiopulmonary bypass. Ann Thorac Surg, 61:88-92 (1996)
doi:10.1016/0003-4975(95)00904-3
PMid:8561645
136. Sellman M, Ivert T, Ronquist G, Caesarini K, Persson L, Semb BK. Central nervous system damage during cardiac surgery assessed by 3 different biochemical markers in cerebrospinal fluid. Scand J Thorac Cardiovasc Surg, 26:39-45 (1992)
137. Kim JS, Yaon SS, Kim YH, Ryu JS. Serial measurements of interleukin-6 transforming growth factor-b, and S-100 protein in patients with acute stroke. Stroke, 27:1553-7 (1996)
138. Kilminster S, Treasure T, McMillan T, Holt DW. Neuropsychological change and S-100 protein release in 130 unselected patients undergoing cardiac surgery. Stroke, 30:1869-74 (1999)
139. Herrmann M, Ebert AD, Galazky I, Wunderlich MT, Kunz WS, Huth C. Neurobehavioral outcome prediction after cardiac surgery: role of neurobiochemical markers of damage to neuronal and glial brain tissue. Stroke, 31:645-50 (2000)
140. Snyder-Ramos SA, Gruhlke T, Bauer H, Bauer M, Luntz AP, Motsch J, Martin E, Vahl CF, Missler U, Wiesmann M, Böttiger BW. Cerebral and extracerebral release of protein S100B in cardiac surgical patients. Anaesthesia, 59:344-9 (2004)
doi:10.1111/j.1365-2044.2004.03663.x
PMid:15023104
141. Marquardt G, Setzer M, Szelenyi A, Seifert V, Gerlach R. Significance of serial S100b and NSE serum measurements in surgically treated patients with spondylotic cervical myelopathy. Acta Neurochir (Wien) (2009) In press.
doi:10.1007/s00701-009-0408-0
PMid:AMBIGUOUS 19499171,19350205
142. Body JJ, Paesmans M, Sculier JP, Dabouis G, Bureau G, Libert P, Berchier MC, Raymakers N, Klastersky J. Monoclonal immunoradiometric assay and polyclonal radioimmunoassay compared for measuring neuronspecific enolase in patients with lung cancer. Clin Chem, 38:748-51 (1992)
143. Isobe T, Takahasi K, Okuyama T. S-100 A0 (alpha alpha) protein is present in neurons of central and peripheral neurons system. J Neurochem, 43:1494-6 (1984)
doi:10.1111/j.1471-4159.1984.tb05415.x
PMid:6387052
144. Kligman D, Hill DC. The S100 protein family. Trends Biochem Sci, 11:437-43 (1988)
doi:10.1016/0968-0004(88)90218-6
PMid:3075365
145. Pahlmann S, Esscher T, Bergvall P, Odelstad L. Purification and characterization of human neuron-specific enolase: radioimmunoassay development. Tumour Biol, 5:127-39 (1984)
146. Hullin DA, Brown K, Kynoch PA, Smith C, Thompson RJ. Purification, radioimmunoassay, and distribution of human brain 14-3-2 protein (nervous-system-specific enolase) in human tissues. Biochim Biophys Acta, 628:98-108 (1980)
147. Kato K, Ishiguro Y, Suzuki F, Ito A, Semba R. Distribution of nervous system-specific forms of enolase in peripheral tissues. Brain Res, 237:441-8 (1982)
doi:10.1016/0006-8993(82)90455-3
PMid:7044473
148. Kato K, Asai R, Shimizu A, Suzuki F, Ariyoshi Y. Immunoassay of three enolase isoenzymes in human serum and in blood cells. Clin Chim Acta, 127:353-63 (1983)
doi:10.1016/0009-8981(83)90162-6
149. Marangos PJ, Campell IC, Schmechel DE, Murphy DL, Goodwin FK. Blood platelets contain a neuron-specific enolase subunit. J Neurochem, 34:1254-8 (1980)
doi:10.1111/j.1471-4159.1980.tb09967.x
PMid:7373305
150. Usui A, Kato K, Abe T, Murase M, Tanaka M, Takenchi E. S-100 a0 protein in blood and urine during open-heart surgery. Clin Chem, 35:1942-44 (1989)
151. Donato R. Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochim Biophys Acta, 1450:191-231 (1999)
doi:10.1016/S0167-4889(99)00058-0
152. Schäfer BW, Heizmann CW. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci, 21:134-40 (1996)
153. Zimmer DB, Cornwall EH, Landar A, Song W. The S100 protein family: history, function, and expression. Brain Res Bull, 37:417- 429 (1995)
doi:10.1016/0361-9230(95)00040-2
PMid:7620916
154. Ingebrigtsen T, Waterloo K, Jacobsen EA, Langbakk B, Romner B. Traumatic brain damage in minor head injury: relation of serum S-100 protein measurements to magnetic resonance imaging and neurobehavioral outcome. Neurosurgery, 45:468-75 (1999)
doi:10.1097/00006123-199909000-00010
PMid:10493368
155. Jonsson H, Johnsson P, Alling C, Westaby S, Blomquist S. Significance of serum S100 release after coronary artery bypass grafting. Ann Thorac Surg, 65:1639-44 (1998)
doi:10.1016/S0003-4975(98)00229-X
PMid:9647073
156. Martens P, Raabe A, Johnsson P. Serum S-100 and neuron-specific enolase for prediction of regaining consciousness after global cerebral ischemia. Stroke, 29:2363-66 (1998)
157. Roine RO, Somer H, Kaste M, Viinikka L, Karonen SL. Neurological outcome after out-of-hospital cardiac arrest: prediction by cerebrospinal fluid enzyme analysis. Arch Neurol, 46:753-56 (1989)
158. Johnsson P, Blomquist S, Luhrs C, Malmkvist G, Alling C, Solem JO, Ståhl E. Neuron-specific enolase increases in plasma during and immediately after extracorporeal circulation. Ann Thorac Surg, 69:750-4 (2000)
doi:10.1016/S0003-4975(99)01393-4
PMid:10750755
159. Böttiger BW, Böhrer H, Böker T, Motsch J, Aulmann M, Martin E. Platelet factor 4 release in patients undergoing cardiopulmonary resuscitation--can reperfusion be impaired by platelet activation? Acta Anaesthesiol Scand, 40(5):631-5 (1996)
doi:10.1111/j.1399-6576.1996.tb04499.x
PMid:8792896
160. Dauberschmidt R, Zinsmeyer J, Mrochen H, Meyer M. Changes of neuronspecific enolase concentration in plasma after cardiac arrest and resuscitation. Mol Chem Neuropathol, 14:237-45 (1991)
161. Martens P. Serum neuron-specific enolase as a prognostic marker for irreversible brain damage in comatose cardiac arrest survivors. Acad Emerg Med, 3:126-31 (1996)
doi:10.1111/j.1553-2712.1996.tb03399.x
PMid:8808372
162. Rosen H, Sunnerhagen KS, Herlitz J, Blomstrand C, Rosengren L. Serum levels of the brain-derived proteins S-100 and NSE predict long-term outcome after cardiac arrest. Resuscitation, 49:183-191 (2001)
doi:10.1016/S0300-9572(00)00348-8
PMid:11382525
163. Hu J, Ferreira A, Van Eldik LJ. S100beta induces neuronal cell death through nitric oxide release from astrocytes. J Neurochem, 69:2294-301 (1997)
164. McAdory BS, Van Eldik LJ, Norden JJ. S100B, a neurotropic protein that modulates neuronal protein phosphorylation, is upregulated during lesioninduced collateral sprouting and reactive synaptogenesis. Brain Res, 813:211-17 (1998)
doi:10.1016/S0006-8993(98)01014-2
PMid:9824701
165. Schaarschmidt H, Prange HW, Reiber H. Neuron-specific enolase concentrations in blood as a prognostic parameter in cerebrovascular diseases. Stroke, 25:558-565 (1994)
166. Schoerkhuber W, Kittler H, Sterz F, Behringer W, Holzer M, Frossard M, Spitzauer S, Laggner AN. Time course of serum neuron-specific enolase. A predictor of neurological outcome in patients resuscitated from cardiac arrest. Stroke, 30:1598-1603 (1999)
167. Zingler VC, Krumm B, Bertsch T, Fassbender K, Pohlmann-Eden B. Early prediction of neurological outcome after cardiopulmonary resuscitation: a multimodal approach combining neurobiochemical and electrophysiological investigations may provide high prognostic certainty in patients after cardiac arrest. Eur Neurol, 49:79-84 (2003)
doi:10.1159/000068503
PMid:12584414
168. Pfeifer R, Borner A, Krack A, Sigusch HH, Surber R, Figulla HR. Outcome after cardiac arrest: predictive values and limitations of the neuroproteins neuron-specific enolase and protein S-100 and the Glasgow coma scale. Resuscitation, 65:49-55 (2005)
doi:10.1016/j.resuscitation.2004.10.011
PMid:15797275
169. Zandbergen EG, Hijdra A, Koelman JH, Hart AA, Vos PE, Verbeek MM, de Haan RJ, PROPAC Study Group. Prediction of poor outcome within the first 3 days of postanoxic coma. Neurology, 66:62-68 (2006)
doi:10.1212/01.wnl.0000191308.22233.88
170. Rech TH, Vieira SR, Nagel F, Brauner JS, Scalco R. Serum neuron-specific enolase as early predictor of outcome after in-hospital cardiac arrest: a cohort study. Crit Care, 10(5):R133 (2006)
doi:10.1186/cc5046
PMid:16978415 PMCid:1751053
171. Stern P, Bartos V, Uhrova J, Bezdickova D, Vanickova Z, Tichy V, Pelinkova K, Prusa R, Zima T. Performance characteristics of seven neuronspecific enolase assays. Tumor Biol, 28:84-92 (2007)
doi:10.1159/000098441
PMid:17259755
172. Schmitt UM, Stieber P, Hasholzner U, Pahl H, Hofmann K, Fateh-Moghadam A. Methodological and clinical evaluation of two automated enzymatic immunoassays as compared with a radioimmunoassay for neuron-specific enolase. Eur J Clin Chem Clin Biochem, 34:679-82 (1996)
173. Reisinger J, Hollinger K, Lang W, Steiner C, Winter T, Zeindlhofer E, Mori M, Schiller A, Lindorfer A, Wiesinger K, Siostrzonek P. Prediction of neurological outcome after cardiopulmonary resuscitation by serial determination of serum neuron-specific enolase. European Heart Journal, 28:52-58 (2007)
doi:10.1093/eurheartj/ehl316
PMid:17060343
174. Hachimi-Idrissi S, Van der Auwera M, Schiettecatte J, Ebinger G, Michotte Y, Huyghens L. S-100 protein as early predictor of regaining consciousness after out of hospital cardiac arrest. Resuscitation, 53:251-57 (2002)
doi:10.1016/S0300-9572(02)00027-8
PMid:12062839
175. Teasdale GM, Pettigrew LE, Wilson JT, Murray G, Jennett B. Analyzing outcome of treatment of severe head injury: a review and update on advancing the use of the Glasgow Outcome Scale. J Neurotrauma, 15(8):587-97 (1998)
doi:10.1089/neu.1998.15.587
PMid:9726258
176. Sunde K, Dunlop O, Rostrup M, Sandberg M, Sjøholm M, Jacobsen D. Determination of prognosis after cardiac arrest may be more difficult after introduction of therapeutic hypothermia. Resuscitation, 69:29-32 (2006)
doi:10.1016/j.resuscitation.2005.12.003
PMid:16517042
177. Tiainen M, Kovala TT, Takkunen OS, Roine RO. Somatosensory and brainstem auditory evoked potentials in cardiac arrest patients treated with hypothermia. Crit Care Med, 33:1736-40 (2005)
doi:10.1097/01.CCM.0000171536.63641.D9
PMid:16096450
178. Oksanen T, Tiainen M, Skrifvars MB, Varpula T, Kuitunen A, Castrén M, Pettilä V. Predictive power of serum NSE and OHCA score regarding 6-month neurologic outcome after out-of-hospital ventricular fibrillation and therapeutic hypothermia. Resuscitation, 80:165-70 (2009)
doi:10.1016/j.resuscitation.2008.08.017
PMid:18954930
179. Pahlmann S, Esscher T, Nilsson K. Expression of gammasubunit of enolase, neuron-specific enolase, in human nonneuroendocrine tumors and derived cell lines. Lab Invest, 54:554-60 (1986)
180. Ramont L, Thoannes H, Volondat A, Chastang F, Millet MC, Maquart FX. Effects of hemolysis and storage condition on neuron-specific enolase (NSE) in cerebrospinal fluid and serum: implications in clinical practice. Clin Chem Lab Med, 43:1215-7 (2005)
doi:10.1515/CCLM.2005.210
PMid:16232088
181. Beaudeux JL, Leger P, Dequen L, Gandjbakhch I, Coriat P, Foglietti MJ. Influence of hemolysis on the measurement of S-100ß protein and neuronspecific enolase plasma concentrations during coronary artery bypass grafting. Clin Chem, 46:989-990 (2000)
182. Sanborn TA, Sleeper LA, Bates ER, Jacobs AK, Boland J, French JK, Dens J, Dzavik V, Palmeri ST, Webb JG, Goldberger M, Hochman JS. Impact of thrombolysis, intra-aortic ballon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. J Am Coll Cardiol, 36:1123-9 (2000)
doi:10.1016/S0735-1097(00)00875-5
PMid:10985715
183. Ohman EM, George BS, White CJ, Kern MJ, Gurbel PA, Freedman RJ, Lundergan C, Hartmann JR, Talley JD, Frey MJ, et al. Use of aortic counterpulsation to improve sustained coronary artery patency during acute myocardial infarction. Circulation, 90:729-39 (1994)
184. Chen EW, Canto JG, Parsons LS, Peterson ED, Littrell KA, Every NR, Gibson CM, Hochman JS, Ohman EM, Cheeks M, Barron HV; Investigators in the National Registry of Myocardial Infarction 2. Relation between hospital intra-aortic Balloon counterpulsation volume an mortality in acute myocardial infarction complicated by cardiogenic shock. Circulation 108:951-7 (2003)
doi:10.1161/01.CIR.0000085068.59734.E4
PMid:12912817
185. Pfeifer R, Ferrari M, Börner A, Deufel T, Figulla HR. Serum concentration of NSE and S-100b during LVAD in non-resuscitated patients. Resuscitation, 79:46-53 (2008)
doi:10.1016/j.resuscitation.2008.04.016
PMid:18617311
186. Omran H, Schmidt H, Hackenbroch M, Illien S, Bernhardt P, von der Recke G, Fimmers R, Flacke S, Layer G, Pohl C, Lüderitz B, Schild H, Sommer T. Silent and apparent cerebral embolism after retrograde catheterisation of the aortic valve in valvular stenosis: a prospective, randomised study. Lancet 361:1241-6 (2003)
doi:10.1016/S0140-6736(03)12978-9
187. Busing KA, Schulte-Sasse C, Fluchter S, Süselbeck T, Haase KK, Neff W, Hirsch JG, Borggrefe M, Düber C. Cerebral infarction: incidence and risk factors after diagnostic and interventional cardiac catheterization - a prospective evaluation at diffusion-weighted MR imaging. Radiology, 235:177-83 (2005)
doi:10.1148/radiol.2351040117
PMid:15731373
188. Kiewitz R, Acklim C, Minder E, huber PR, Schaefer BW, Heizmann CW. S 100A1, a new marker for acute myocardial ischemia. Biochem Biophys Res Commun, 274:865-71 (2000)
doi:10.1006/bbrc.2000.3229
PMid:10924368
189. Haimoto H, Hosoda S, Kato K. Differential distribution of immunoreactive S100-α and S100-β proteins in normal non nervous human tissues. Lab Invest, 57:489-97 (1987)
190. Tsoporis JN, Marks A, Kahn HJ, Butany JW, Liu PP, O'Hanlon D, Parker TG. S 100β inhibits α1-adrenergic induction of the hypertrophic phenotype in cardiac myocytes. J Biol Chem 272:31915-21 (1997)
doi:10.1074/jbc.272.50.31915
PMid:9395540
191. Tsoporis JN, Marks A, Kahn HJ, Butany JW, Liu PP, O'Hanlon D, Parker TG. Inhibition of norepinephrine induced cardiac hypertrophy in S100β transgenic mice. J Clin Invest, 102:1609-16 (1998)
doi:10.1172/JCI3077
PMid:9788975 PMCid:509012
192. Booth CM, Boone RH, Tomlinson G, Detsky AS. Is this patient dead, vegetative, or severely neurologically impaired? Assessing outcome for comatose survivors of cardiac arrest. JAMA, 291:870-9 (2004)
doi:10.1001/jama.291.7.870
PMid:14970067
193. Madl C, Kramer L, Domanovits H, Woolard RH, Gervais H, Gendo A, Eisenhuber E, Grimm G, Sterz F. Improved outcome prediction in unconscious cardiac arrest survivors with sensory evoked potentials compared with clinical assessment. Crit Care Med 28:721-6 (2000)
doi:10.1097/00003246-200003000-00020
PMid:10752821
194. Rothstein T, Thomas E, Sumi S. Predicting outcome in hypoxic-ischemic coma. A prospective clinical and electrophysiological study. Electroencephalogr Clin Neurophysiol, 79:101-07 (1991)
doi:10.1016/0013-4694(91)90046-7
PMid:1713822
Key Words: Myoepithelial cells, DCIS, tumor progression, tumor microenvironment, basement membrane, matrix metalloproteinases, natural tumor suppressors, Review
Send correspondence to: Kounosuke Watabe, Department of Medical Microbiology/Immunology and Cell Biology, School of Medicine, Southern Illinois University, 825 N. Rutledge Springfield IL 62702, USA, Tel: 217-545-3969, Fax: 217-545-3227, E-mail:kwatabe@siumed.edu